The National Pharmaceutical Pricing Authority (NPPA) said there has been “a significant price reduction in cancer drug prices since March 2017” in a tweet. These price reductions reportedly apply to Iressa of AstraZeneca Pharma India; Dr Reddy’s laboratories’ Grafeel; Natco, and Emcure pharmaceuticals, among many others.
The price reductions range from 86% to 13% respectively, providing dozens of valuable medications to country residents for intensely more affordable costs.
The NPPA also applied price reductions to a dozen various diabetes medications with cuts ranging from 42 to 13%.
In addition to their efforts in making pharmaceuticals more affordable, the NPPA is currently investigating 24 different hospitals that have received patient complaints about being over-charged.